Kevin Grogan

Adam Steensberg tells analysts that KOLs like the value proposition that has been built for Roche-partnered petrelintide, "a benign, highly tolerable therapy delivering double-digit weight loss."

The Denmark-headquartered firm has acquired the rights to dersimelagon from Japan's Tanabe Pharma, a potential competitor in the protoporphyria space to Clinuvel Pharmaceutical's Scenesse.

An Evaluate webinar shines the spotlight on the trends shaping the world's fastest-moving market.

The Danish drugmaker can boast a transformed pipeline and steady revenue rises that should ensure a sustainable healthy future, according to CEO Charl van Zyl.

The Danish firm has initiated a Phase I/IIa trial on a long-acting corticotropin-releasing hormone receptor 2 agonist which shows pipeline-in-a-product potential.

France's Valneva's travel health products are suffering a fall in demand but that is not the case for its Denmark-headquartered competitor.

The Swedish group has filed paperwork for a potential US NASDAQ IPO which could broaden access to investors as it prepares for a regulatory decision and possible launch of its kidney transplant therapy before the end of the year.

The Germany-based biotech has decided to bolster the balance sheet as it prepares for key readouts on its cell therapy and bispecific candidates.

AstraZeneca and Amgen's thymic stromal lymphopoietin inhibitor, which is already approved for severe asthma and chronic rhinosinusitis with nasal polyps, is heading to the regulators after hitting its primary goals in an eosinophilic esophagitis trial.

The firm has revealed the extent of the win seen in the ACACIA-HCM study in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, a setting where Bristol Myers Squibb's rival cardiac myosin inhibitor Camzyos failed.